Merck Just Spent $10 Billion on a Lung Drug. Here's Why.
Merck is dropping $10 billion to buy Verona Pharma and its first-in-class COPD drug, ensifentrine. With Keytruda's $33 billion revenue stream facing patent expiration in 2028, this deal is less about lungs and more about survival.
The Clock Is Ticking in Rahway
Somewhere inside Merck's New Jersey headquarters, there's a countdown clock. It doesn't hang on a wall or flash on a screen. But everyone there can feel it ticking. In roughly two years, Keytruda, the cancer blockbuster that generates an estimated $29.5 billion in annual revenue, starts losing its patent protection. Biosimilar competitors will flood the market. And Merck's single biggest revenue engine will begin to sputter.
So what do you do when your golden goose is aging out? You go shopping.
On July 9, Merck announced it would acquire Verona Pharma for approximately $10 billion in an all-cash deal. The price: $107 per American Depositary Share, representing a 23% premium over Verona's last closing price on the Nasdaq. The prize: a first-in-class respiratory drug called ensifentrine, sold under the brand name Ohtuvayre, which the FDA approved in 2024 for COPD maintenance therapy.
This isn't just a bolt-on deal. It's a strategic pivot. Merck, long synonymous with cancer drugs, is betting billions that lungs are the next frontier.
What Merck Is Actually Buying
Let's talk about ensifentrine, because it's the reason this deal exists.
COPD (chronic obstructive pulmonary disease) is one of those conditions that affects a staggering number of people but rarely makes headlines. Think of it as the lungs slowly losing their ability to move air in and out, like trying to breathe through a straw that keeps getting narrower. It's the third leading cause of death worldwide, and the drugs used to treat it haven't seen a genuinely new mechanism of action in over 20 years.
That's what makes ensifentrine interesting. It's a dual PDE3/PDE4 inhibitor, which in plain English means it works two jobs at once: it opens up the airways (bronchodilation) and reduces inflammation. Most existing COPD drugs do one or the other. Ensifentrine does both in a single inhaled treatment.
The clinical data backed it up. In the pivotal phase 3 trials, ensifentrine hit its primary endpoints, showing statistically significant improvements in lung function at 12 weeks. Pooled data from the full program showed something even more compelling: a (called exacerbations) over 24 weeks compared to placebo. For COPD patients, fewer exacerbations means fewer ER visits, fewer hospitalizations, and a meaningfully better quality of life.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
ENHANCE-1 and ENHANCE-2
40% reduction in COPD flare-ups
The FDA agreed. It approved Ohtuvayre, making it the first inhaled product with a new mechanism for COPD in more than two decades. That's the kind of "first" that pharmaceutical companies build entire franchises around.
The Keytruda Problem Nobody Can Ignore
To understand why Merck wrote a $10 billion check for a lung drug, you have to understand the Keytruda problem.
Keytruda (pembrolizumab) is a cancer immunotherapy that became the best-selling drug on the planet. It treats more than 30 types of cancer. It's the backbone of Merck's revenue. And it's approaching the edge of a cliff.
The core U.S. patents are set to expire in 2028, with Merck suggesting some additional patents could extend protection into 2029. But the direction of travel is clear: biosimilars are coming, and when they arrive, they'll erode Keytruda's pricing power the way generic drugs always do.
Imagine you're a restaurant that makes 40% of its revenue from one dish. Now imagine everyone in town is about to start serving the same dish at half the price. That's the Keytruda patent cliff in a nutshell.
Merck has been preparing for this moment. The company reportedly plans to create a separate cancer division to help the business absorb the transition more cleanly. But organizational reshuffling only goes so far. Merck needs new revenue streams, and it needs them to be big enough to matter against a massive revenue hole.
That's where the Verona deal fits. It's not about replacing Keytruda overnight (nothing can). It's about building a diversified portfolio across respiratory care, vaccines, and animal health so that when Keytruda's revenue declines, Merck doesn't decline with it.
A $10 Billion Bet on Breathing
The global COPD treatment market is enormous, estimated at roughly $21 to $26 billion in 2025 depending on how you define the scope. It's growing at a moderate clip, with forecasted annual growth rates between 4% and 8%. That's not a hypergrowth market, but it's a massive, steady one. Think of it less like a tech startup and more like commercial real estate: reliable, enormous, and rewarding for whoever owns prime properties.
Right now, COPD treatment is dominated by entrenched drug classes: long-acting bronchodilators (LAMAs, LABAs), inhaled corticosteroids, and triple-therapy combinations. These drugs work, but they've been around for years, and there's been a real hunger for something mechanistically different. Ensifentrine is that something.
Beyond COPD maintenance, Verona's pipeline includes studies in non-cystic fibrosis bronchiectasis (a chronic condition where the airways become damaged and widened) and a planned phase 2b combination study pairing ensifentrine with glycopyrrolate, an existing bronchodilator, for COPD. If ensifentrine plays well with others, the addressable market could grow significantly.
For Merck, this creates the foundation for a respiratory franchise. Not just a single product, but a platform with multiple shots on goal.
The Deal Structure: Clean and Simple
The mechanics of this acquisition are straightforward, even if the legal structure has a British accent. Verona Pharma is a UK-incorporated company (despite trading on the Nasdaq), so the deal is structured as a court-sanctioned scheme of arrangement under UK law. That means it needs Verona shareholder approval, a sign-off from the U.K. High Court, and standard regulatory clearances.
Merck is paying $107 per ADS in cash, with each ADS representing eight Verona ordinary shares. The company plans to finance the purchase with a mix of cash on hand, commercial paper, and new debt. One detail worth noting: Verona had roughly $200 million in cash and investments on its books, putting the net deal value closer to $9.8 billion.
The 23% premium Merck paid wasn't outrageous by biotech M&A standards. This wasn't a distressed acquisition or a rescue mission. Merck paid full price for a company that Wall Street already believed in.
What Wall Street Thinks
The early reaction has been broadly positive. Verona shares moved up after the announcement, which is the market's way of saying "this price looks fair." Merck's stock also caught a tailwind in sessions where healthcare names were strong, though it's hard to isolate exactly how much of that was Verona-specific.
The strategic logic resonated with analysts. Coverage framed the deal as Merck's largest acquisition since Prometheus Biosciences, underscoring its importance to the company's M&A playbook. Most commentary centered on two themes: the strength of ensifentrine as a first-in-class COPD therapy, and the urgency of diversifying before Keytruda's patents expire.
That said, the skeptics have a point too. Ensifentrine still needs to prove it can capture meaningful market share in a COPD landscape dominated by cheaper, well-established drugs. The drug works differently, but "different" doesn't automatically mean "dominant." Merck will need to execute a strong commercial launch and convince pulmonologists that ensifentrine deserves a spot in their prescribing rotation alongside (or instead of) existing options.
The Bigger Picture
Zoom out, and this deal tells a story about where Big Pharma is headed. The era of single-drug dominance is ending. Keytruda was a once-in-a-generation asset, but patent cliffs are the industry's version of gravity: you can fight them, but you can't escape them.
Merck's answer is diversification, and the Verona acquisition is the clearest signal yet of what that looks like. The company isn't just buying a drug; it's buying an entire therapeutic area. Respiratory medicine is large, chronic, and underinnovated. That's exactly the kind of market where a first-in-class drug can carve out a durable franchise.
The next 24 months will tell us whether this was a brilliant piece of strategic foresight or an expensive insurance policy that paid out less than expected. Ensifentrine has to go from promising approval to commercial powerhouse. Merck has to integrate a UK-based biotech into its sprawling global operation. And the Keytruda cliff has to be managed in parallel.
It's a lot of plates to spin. But when billions in revenue are on the line, you don't sit around waiting. You write a $10 billion check and bet on lungs.
Deals & M&A
5 min read
Bayer's $2.2 Billion Bet on American Soil
Bayer is dropping $2.2 billion on its first-ever pharma manufacturing campus in North America, picking New Albany, Ohio, as the site for a massive bet on domestic drug production. It's part of a reshoring tidal wave that's rewriting the rules of where medicine gets made.
